Uma análise da vendas da indústria farmacêutica entre países foi publicada por pesquisadores da Universidade Erasmus, de Roterdam, Holanda. (texto completo aqui) Destaca-se a questão do marketing direto, com sendo um incentivador de vendas. O Brasil ainda não caiu nesse conto, apesar de tentativas disfarçadas de divulgação de medicamentos tanto na publicidade como no "publijornalismo". Que assim se mantenha.
Sales Growth of New Pharmaceuticals Across the Globe: The Role of Regulatory Regimes
Stefan Stremersch and Aurélie LemmensErasmus Research Institute of Management (ERIM) – May 2008RSM Erasmus University / Erasmus School of Economics - Erasmus Universiteit Rotterdam
“…..Prior marketing literature has overlooked the role of regulatory regimes in explaining international sales growth of new products. This paper addresses this gap in the context of new pharmaceuticals (15 new molecules in 34 countries) and sheds light on the effect regulatory regimesni have on new drug sales across the globe. Based on a time-varying coefficient model, we find that differences in regulation substantially contribute to cross-country variation in sales. One of the regulatory constraints investigated, i.e. manufacturer price controls, has a positive effect on drug sales. The other forms of regulation such as restrictions of physician prescription budgets and the prohibition of direct-to-consumer advertising tend to hurt sales. The effect of manufacturer price controls is similar for newly launched and mature drugs. In contrast, regulations on physician prescription budget and direct-to-consumer advertising have a differential effect for newly launched and mature drugs. While the former hurts mature drugs more, the latter has a larger effect on newly launched drugs. In addition to these regulatory effects, we find that national culture, economic wealth, introduction timing, lagged sales and competition, also affect drug sales. Our findings may be used as input by managers for international launch and sales decisions. They may also be used by public policy administrators to compare drug sales in their country to other countries and to assess the role of regulatory regimes therein….”
Nenhum comentário:
Postar um comentário